Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Signs Columbia University CLIA Lab to Validate microRNA-Based CUP Dx

NEW YORK (GenomeWeb News) — Rosetta Genomics today said that a Columbia University Medical Center lab will validate the company’s microRNA-based diagnostics program for Cancer of Unknown Primary.
The agreement calls for the company to provide the school’s Clinical Laboratory Improvement Amendments-certified lab with its protocol for diagnosing the primary origin of metastatic cancers, which will then be tested and validated using blinded samples provided by the medical center.
The alliance is Rosetta Genomics' first agreement that aims to clinically validate one of its cancer diagnostics. The company is developing several diagnostics at its R&D facilities in Israel and the United States.
The CUP diagnostic, currently in the final stages of development, is designed to help clinicians identify the origin of tumors that have metastasized throughout the body.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.